Etrade Capital Management Has Cut Its Abbott Laboratories (ABT) Stake; Ceridian (CEN)’s Sentiment Is 1.73

August 12, 2018 - By Jack Shaw

Abbott Laboratories (NYSE:ABT) Logo

Ceridian Corp (CEN) investors sentiment decreased to 1.73 in Q1 2018. It’s down -0.77, from 2.5 in 2017Q4. The ratio has dropped, as 19 active investment managers started new or increased holdings, while 11 decreased and sold their positions in Ceridian Corp. The active investment managers in our database now have: 4.58 million shares, up from 4.15 million shares in 2017Q4. Also, the number of active investment managers holding Ceridian Corp in top ten holdings was flat from 1 to 1 for the same number . Sold All: 3 Reduced: 8 Increased: 11 New Position: 8.

Etrade Capital Management Llc decreased Abbott Laboratories (ABT) stake by 24.17% reported in 2018Q1 SEC filing. Etrade Capital Management Llc sold 10,083 shares as Abbott Laboratories (ABT)’s stock rose 3.04%. The Etrade Capital Management Llc holds 31,638 shares with $1.90 million value, down from 41,721 last quarter. Abbott Laboratories now has $112.33B valuation. The stock decreased 0.94% or $0.61 during the last trading session, reaching $64.03. About 3.84 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 41.91% since August 12, 2017 and is uptrending. It has outperformed by 29.34% the S&P500. Some Historical ABT News: 23/05/2018 – Lupe Valdez Prepares to Face Greg Abbott in Texas: `This Election Is Not Going to Be Bought’; 18/04/2018 – Abbott Labs Sees FY Cont Ops EPS $1.23-$1.33; 05/04/2018 – ABBOTT SAYS ISS REPORT INCORRECT, UNRELIABLE; 19/03/2018 – ABBOTT’S MITRACLIP THERAPY GETS NATIONAL REIMBURSEMENT IN JAPAN; 17/04/2018 – FDA: ABT IMPLANTABLE CARDIAC DEVICES FIRMWARE UPDATE AVAILABLE; 18/04/2018 – Abbott Labs Sees 2Q Adj EPS 70c-Adj EPS 72c; 18/05/2018 – ABBOTT SAYS VARIOUS EXPLOSIVE DEVICES HAVE BEEN DETECTED, INCLUDING ONE C02 DEVICE, ONE MOLOTOV COCKTAIL; 18/05/2018 – ABBOTT: EXPLOSIVE DEVICES APPARENTLY WERE MADE BY THE SHOOTER; 02/05/2018 – Abbott’s XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease; 18/05/2018 – ABBOTT SAYS TWO WEAPONS USED IN ATTACK – SHOTGUN AND .38 REVOLVER, BOTH OBTAINED BY SHOOTER FROM FATHER

More news for Abbott Laboratories (NYSE:ABT) were recently published by: Seekingalpha.com, which released: “If AbbVie Is A Buy, What About Abbott?” on July 20, 2018. Seekingalpha.com‘s article titled: “House repeals tax on medical devices” and published on July 25, 2018 is yet another important article.

Etrade Capital Management Llc increased Delta Air Lines Inc (NYSE:DAL) stake by 10,205 shares to 18,458 valued at $1.01 million in 2018Q1. It also upped Cvs Health Corp (NYSE:CVS) stake by 5,671 shares and now owns 85,238 shares. Bp Plc (NYSE:BP) was raised too.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on October, 17. They expect $0.74 EPS, up 12.12% or $0.08 from last year’s $0.66 per share. ABT’s profit will be $1.30 billion for 21.63 P/E if the $0.74 EPS becomes a reality. After $0.73 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 1.37% EPS growth.

Among 4 analysts covering Abbott Labs (NYSE:ABT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Abbott Labs had 4 analyst reports since April 18, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, July 19 by Stifel Nicolaus. The firm has “Neutral” rating by Citigroup given on Tuesday, April 24. On Wednesday, April 18 the stock rating was maintained by Jefferies with “Buy”.

Since February 16, 2018, it had 1 insider buy, and 21 selling transactions for $8.90 million activity. Bracken Sharon J sold $125,909 worth of stock. Fussell Stephen R sold 56,401 shares worth $3.36 million. On Wednesday, February 28 MANNING JOSEPH J sold $84,344 worth of Abbott Laboratories (NYSE:ABT) or 1,430 shares. $2.43M worth of Abbott Laboratories (NYSE:ABT) was bought by STARKS DANIEL J. The insider Blaser Brian J sold 15,100 shares worth $965,789. Watkin Jared had sold 996 shares worth $58,635. Another trade for 459 shares valued at $27,213 was sold by PEDERSON MICHAEL J.

Investors sentiment decreased to 0.83 in Q1 2018. Its down 0.08, from 0.91 in 2017Q4. It dropped, as 44 investors sold ABT shares while 606 reduced holdings. 126 funds opened positions while 411 raised stakes. 1.22 billion shares or 0.54% more from 1.22 billion shares in 2017Q4 were reported. Bragg Financial Advisors accumulated 73,834 shares or 0.65% of the stock. Centre Asset Mngmt invested 0.89% of its portfolio in Abbott Laboratories (NYSE:ABT). Catawba Mngmt Va accumulated 0.6% or 41,666 shares. British Columbia Invest Mngmt Corp accumulated 681,860 shares. Bender Robert And Associates owns 0.39% invested in Abbott Laboratories (NYSE:ABT) for 11,691 shares. Davis R M Incorporated reported 0.09% of its portfolio in Abbott Laboratories (NYSE:ABT). Engineers Gate Manager Limited Partnership holds 66,060 shares. Cincinnati Specialty Underwriters Insurance Co reported 27,200 shares stake. Ramsay Stattman Vela Price Inc owns 136,964 shares. Pure Financial Advsr Inc, a California-based fund reported 11,435 shares. Bbr Partners Lc has 6,701 shares. D Scott Neal holds 0.05% or 1,453 shares in its portfolio. Folger Nolan Fleming Douglas Capital Management accumulated 95,353 shares. 29,647 were accumulated by Essex Fincl Ser. Utd Fire Group holds 4.62% of its portfolio in Abbott Laboratories (NYSE:ABT) for 215,000 shares.

Another recent and important Center Coast Brookfield MLP & E (NYSE:CEN) news was published by Nasdaq.com which published an article titled: “Center Coast Brookfield MLP & Energy Infrastructure Fund Announces Portfolio Manager Webcast” on July 19, 2018.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts